Clinical Trials Logo

Citation(s)

  •   Vij R, Kim H, Park H, Cheng T, Lotfi D, Chang D
    Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program. Stem Cell Res Ther. 2023 Oct 5;14(1):287. doi: 10.1186/s1328

Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Patients With Post-COVID-19 Syndrome

Details for clinical trial NCT04798066